|
1
|
Hergovich A: MOB control: Reviewing a
conserved family of kinase regulators. Cell Signal. 23:1433–1440.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hergovich A: Regulation and functions of
mammalian LATS/NDR kinases: Looking beyond canonical Hippo
signalling. Cell Biosci. 3:322013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hergovich A: The roles of NDR protein
kinases in Hippo signalling. Genes (Basel). 7:E212016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gundogdu R and Hergovich A: The possible
crosstalk of MOB2 with NDR1/2 kinases in cell cycle and DNA damage
signaling. J Cell Signal. 1:1252016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kohler RS, Schmitz D, Cornils H, Hemmings
BA and Hergovich A: Differential NDR/LATS interactions with the
human MOB family reveal a negative role for human MOB2 in the
regulation of human NDR kinases. Mol Cell Biol. 30:4507–4520. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bothos J, Tuttle RL, Ottey M, Luca FC and
Halazonetis TD: Human LATS1 is a mitotic exit network kinase.
Cancer Res. 65:6568–6575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gomez V, Gundogdu R, Gomez M, Hoa L,
Panchal N, O'Driscoll M and Hergovich A: Regulation of DNA damage
responses and cell cycle progression by hMOB2. Cell Signal.
27:326–339. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu W, Zhang X, Qin H, Peng W, Xue Q, Lv H,
Zhang H, Qiu Y, Cheng H, Zhang Y, et al: Modulation of tumor cell
migration, invasion and cell-matrix adhesion by human monopolar
spindle-one-binder 2. Oncol Rep. 33:2495–2503. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tamaskovic R, Bichsel SJ, Rogniaux H,
Stegert MR and Hemmings BA: Mechanism of Ca2+-mediated
regulation of NDR protein kinase through autophosphorylation and
phosphorylation by an upstream kinase. J Biol Chem. 278:6710–6718.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vichalkovski A, Gresko E, Cornils H,
Hergovich A, Schmitz D and Hemmings BA: NDR kinase is activated by
RASSF1A/MST1 in response to Fas receptor stimulation and promotes
apoptosis. Curr Biol. 18:1889–1895. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang L, Tang F, Terracciano L, Hynx D,
Kohler R, Bichet S, Hess D, Cron P, Hemmings BA, Hergovich A and
Schmitz-Rohmer D: NDR functions as a physiological YAP1 kinase in
the intestinal epithelium. Curr Biol. 25:296–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang L, Xue G, Grzmil M, Yang Z,
Hergovich A, Hollaender GA, Stein JV, Hemmings BA and Matthias P:
The kinases NDR1/2 act downstream of the Hippo homolog MST1 to
mediate both egress ofthymocytes from the thymus and lymphocyte
motility. Sci Signal. 8:ra1002015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang X, George J, Deb S, Degoutin JL,
Takano EA, Fox SB; AOCS Study group; Bowtell DD and Harvey KF: The
Hippo pathway transcriptional co-activator, YAP, is an ovarian
cancer oncogene. Oncogene. 30:2810–2822. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu J, Li J, Li P, Wang Y, Liang Z, Jiang
Y, Li J, Feng C, Wang R, Chen H, et al: Loss of DLG5 promotes
breast cancer malignancy by inhibiting the Hippo signaling pathway.
Sci Rep. 7:421252017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu FX, Zhang Y, Park HW, Jewell JL, Chen
Q, Deng Y, Pan D, Taylor SS, Lai ZC and Guan KL: Protein kinase A
activates the Hippo pathway to modulate cell proliferation and
differentiation. Genes Dev. 27:1223–1232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang S, Zhang L, Purohit V, Shukla SK,
Chen X, Yu F, Fu K, Chen Y, Solheim J, Singh PK, et al: Active YAP
promotes pancreatic cancer cell motility, invasion and
tumorigenesis in a mitotic phosphorylation-dependent manner through
LPAR3. Oncotarget. 6:36019–36031. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moroishi T, Park HW, Qin B, Chen Q, Meng
Z, Plouffe SW, Taniguchi K, Yu FX, Karin M, Pan D and Guan KL: A
YAP/TAZ-induced feedback mechanism regulates Hippo pathway
homeostasis. Genes Dev. 29:1271–1284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hayashi H, Higashi T, Yokoyama N, Kaida T,
Sakamoto K, Fukushima Y, Ishimoto T, Kuroki H, Nitta H, Hashimoto
D, et al: An imbalance in TAZ and YAP expression in hepatocellular
carcinoma confers cancer stem cell-like behaviors contributing to
disease progression. Cancer Res. 75:4985–4997. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mo JS, Park HW and Guan KL: The Hippo
signaling pathway in stem cell biology and cancer. EMBO Rep.
15:642–656. 2014.PubMed/NCBI
|
|
21
|
Mo JS, Yu FX, Gong R, Brown JH and Guan
KL: Regulation of the Hippo-YAP pathway by protease-activated
receptors (PARs). Genes Dev. 26:2138–2143. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harvey KF, Zhang X and Thomas DM: The
Hippo pathway and human cancer. Nat Rev Cancer. 13:246–257. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Haskins JW, Nguyen DX and Stern DF:
Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo
pathway target genes and promote cell migration. Sci Signal.
7:ra1162014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huelter-Hassler D, Tomakidi P, Steinberg T
and Jung BA: Orthodontic strain affects the Hippo-pathway effector
YAP concomitant with proliferation in human periodontal ligament
fibroblasts. Eur J Orthod. 39:251–257. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Oh H and Irvine KD: Yorkie: The final
destination of Hippo signaling. Trends Cell Biol. 20:410–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vahid S, Thaper D, Gibson KF, Bishop JL
and Zoubeidi A: Molecular chaperone Hsp27 regulates the Hippo tumor
suppressor pathway in cancer. Sci Rep. 6:318422016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hergovich A, Schmitz D and Hemmings BA:
The human tumour suppressor LATS1 is activated by human MOB1 at the
membrane. Biochem Biophys Res Commun. 345:50–58. 2006. View Article : Google Scholar : PubMed/NCBI
|
